在结肠直肠癌和侵袭性乳腺癌中使用化学抗原受体-T细胞疗法的最新临床前景和挑战
Yu Cao1, Sergey K Efetov1, Mingze He1
1I.M. Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation (Sechenov University), Moscow, 119991, Russia.
Archivum immunologiae et therapiae experimentalis
|August 11, 2023
概括
化学抗原受体 (CAR) -T细胞疗法在结直肠癌 (CRC) 和乳腺癌 (BC) 方面表现有前途. 本综述探讨了治疗这些固体瘤的新型CAR-T目标和挑战.
科学领域:
- 在瘤学瘤学.
- 免疫治疗是一种免疫疗法.
- 癌症研究 癌症研究
背景情况:
- 在全球范围内,结肠直肠癌 (CRC) 和乳腺癌 (BC) 的发病率和死亡率正在上升.
- 目前治疗晚期CRC和BC的疗法有效性有限,预后不佳.
- 化学抗原受体 (CAR) -T细胞疗法在血液恶性瘤中取得了成功.
研究的目的:
- 审查关于CRC和BC的新CAR-T目标的最新信息.
- 讨论阻碍固体瘤CAR-T疗法发展的挑战.
- 为研究人员和临床医生提供CAR-T免疫疗法领域的见解.
主要方法:
- 关于CAR-T治疗固体瘤的最新进展的文献综述.
- 识别和讨论与CRC和BC相关的新型CAR-T标抗原.
- 在固体瘤治疗中分析与CAR-T细胞疗法相关的挑战.
主要成果:
- 已经确定了CRC和BC中CAR-T治疗的几个新目标,包括GUCY2C,CLEC14A和HER2.
- 关键的挑战包括免疫抑制瘤微环境,缺乏瘤特异性抗原和潜在的副作用.
- 目前正在进行的临床试验正在评估CRC和BC的CAR-T免疫疗法.
结论:
- 卡尔-T细胞疗法具有治疗CRC和BC的潜力,但仍然存在重大障碍.
- 克服针对固体瘤的挑战对于治疗进步至关重要.
- 需要对新的目标和战略进行进一步的研究,以提高CAR-T的有效性.
更多相关视频
09:56A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy
Published on: February 21, 2025
650
09:34Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
Published on: February 17, 2022
3.4K
相关概念视频
Tumor Immunotherapy
557
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
557
Targeted Cancer Therapies
7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.7K
Treatment Resistant Cancers
3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K
Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
